Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun;10(6):375-376.
doi: 10.1016/S2213-8587(22)00108-5. Epub 2022 Apr 22.

SURPASSing the current dogma: is our framework shifting?

Natasha P Malkani  1 , Vanita R Aroda  2
Affiliations
Comment

SURPASSing the current dogma: is our framework shifting?

Natasha P Malkani et al. Lancet Diabetes Endocrinol. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

VRA has served as a consultant for Applied Therapeutics, Fractyl, Novo Nordisk, Pfizer, and Sanofi; has a spouse who is employed by Janssen; and has had research support (institutional clinical trial contracts) from Applied Therapeutics/Medpace, Eli Lilly, Premier/Fractyl, Novo Nordisk, and Sanofi/Medpace. NPM declares no competing interests.

Comment on

References

    1. Battelino T, Bergenstal RM, Rodríguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022; published online April 22. 10.1016/S2213-8587(22)00077-8. - DOI - PubMed
    1. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet; 398: 583–98. - PubMed
    1. Draznin B, Aroda VR, Bakris G, et al. Glycemic targets: standards of medical care in diabetes—2022. Diabetes Care 2022; 45 (suppl 1): S83–96. - PubMed
    1. Aroda VR. A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab 2018; 20 (suppl 1): 22–33. - PubMed
    1. Frías JP. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab 2020; 15: 379–94. - PubMed